What is aligos Therapeutics'(ALGs) stock price forecast for 2021?
The 12-month stock price forecast is 35.25, which is an increase of 197.22% from the latest price. SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...
Who is aligos Therapeutics?
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
Is ALGs stock a buy or sell?
According to 4 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is 35.25, which is an increase of 197.22% from the latest price.
Is ALGS stock a buy right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last year. There are currently 4 hold...
Will Aligos Therapeutics' stock price go up in 2022?
5 brokers have issued 12-month price targets for Aligos Therapeutics' stock. Their forecasts range from $4.00 to $12.00. On average, they anticipat...
How has Aligos Therapeutics' stock performed in 2022?
Aligos Therapeutics' stock was trading at $11.87 at the beginning of 2022. Since then, ALGS stock has decreased by 87.0% and is now trading at $1.5...
When is Aligos Therapeutics' next earnings date?
Aligos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Aligos Therapeutics' earnings last quarter?
Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced its quarterly earnings data on Wednesday, May, 4th. The company reported ($0.84) earnings per sha...
Who are Aligos Therapeutics' key executives?
Aligos Therapeutics' management team includes the following people: Dr. Lawrence M. Blatt MBA , Ph.D., CEO & Chairman (Age 60, Pay $900.08k) Dr....
Who are some of Aligos Therapeutics' key competitors?
Some companies that are related to Aligos Therapeutics include Tenaya Therapeutics (TNYA) , Autolus Therapeutics (AUTL) , Social Capital Suvrett...
When did Aligos Therapeutics IPO?
(ALGS) raised $150 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00...
What is Aligos Therapeutics' stock symbol?
Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS."
What is Aligos Therapeutics?
Is Aligos on track?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
Recently Viewed Tickers
Advancement of Aligos' drug candidates continues to be on track Advancement of Aligos' drug candidates continues to be on track
Aligos Therapeutics Inc
Visit a quote page and your recently viewed tickers will be displayed here.
What is the ticker symbol for Aligos Therapeutics?
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections.
What is Aligos Therapeutics?
Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS."
How to contact Lifesciadvisors?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-Ã agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Does Aligos Therapeutics pay dividends?
The company can be reached via phone at 800-466-6059 or via email at [email protected].
What is Aligos Therapeutics?
Aligos Therapeutics does not currently pay a dividend.
Where is Aligos Therapeutics located?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.